{
    "clinical_study": {
        "@rank": "100987", 
        "arm_group": [
            {
                "arm_group_label": "Infants", 
                "arm_group_type": "Experimental", 
                "description": "Patients \u2265 6 months of age at time of study enrollment"
            }, 
            {
                "arm_group_label": "Babies", 
                "arm_group_type": "Experimental", 
                "description": "Patients \u2265 4 months of age but < 6 months of age"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to test the safety of the treatment combination of alternating\n      standard chemotherapy and another (melphalan) chemotherapy at different interval schedules.\n      Researchers want to find out what effects, good and/or bad, the treatment combination has on\n      the patients and their retinoblastoma."
        }, 
        "brief_title": "Alternating Systemic Chemotherapy and Intra-Arterial Melphalan Chemotherapy in Children With Intra-Ocular Retinoblastoma", 
        "completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Advanced Intra-Ocular Retinoblastoma", 
            "Retinoblastoma"
        ], 
        "condition_browse": {
            "mesh_term": "Retinoblastoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age greater than or equal to 4 months.\n\n               1. Age greater than or equal to 4 months but less than 6 months of age can receive\n                  up to 2 cycles of systemic chemotherapy to bridge until 6 months (cohort 2).\n\n               2. Age greater than or equal to 6 months at study entry (cohort 1) to receive\n                  alternating therapy.\n\n          -  Intraocular retinoblastoma not previously treated with systemic chemotherapy,\n             radiation therapy, or IA therapy. Local retinal therapy such as laser\n             photocoagulation and cryotherapy will be permitted.\n\n          -  Unilateral or bilateral RB patients are eligible\n\n          -  Patients will be registered on study based on the local exam under anesthesia (EUA)\n             done for diagnostic purposes prior to study entry. The EUA done at study entry should\n             be done within 14 days prior to study entry\n\n          -  Patients may have had enucleation of one eye, as long as the remaining eye meets the\n             eligibility criteria\n\n          -  Involved eye(s) must meet the definition for International Classification of\n             Retinoblastoma Group D or E\n\n               1. Group D eye can be unilateral or bilateral\n\n               2. Group E eye will be eligible if bilateral involvement or unilateral involvement\n                  in a child less than 1 year of age\n\n               3. Patients with bilateral disease in which one of the eyes has Group C disease are\n                  not eligible until interval level 2 in cohort 1 and are not eligible for cohort\n                  2\n\n          -  Adequate Renal Function defined as: creatinine clearance or radioisotope GFR \u00b3\n             70mL/min/1.73 m2 OR a serum creatinine based on age and gender as follows:\n\n        The threshold creatinine values in this Table were derived from the Schwartz formula for\n        estimating GFR (Schwartz et al. J. Peds, 106:522, 1985) utilizing child length and stature\n        data published by the CDC\n\n          -  Adequate hematological function defined as:\n\n               1. Absolute Neutrophil Count > 750/microliter\n\n               2. Platelet Count > 100,000/microliter\n\n          -  Adequate liver function defined as total bilirubin should be less than or equal to\n             1.5 x upper limit of normal (ULN) for age and SGOT (AST) and SGPT (ALT) < 5 x upper\n             limit of normal (ULN) for age\n\n          -  Adequate coagulation system as defined as an international normalized ratio (INR) of\n             less than 1.4 and a partial thromboplastin time (PTT) of less than 34\n\n          -  The effects of melphalan, carboplatin, etoposide and vincristine are harmful on the\n             developing human fetus. For this reason, women of child-bearing potential and men\n             must agree to use adequate contraception: hormonal or barrier method of birth\n             control; abstinence, prior to study entry and for the duration of study\n             participation. Should a woman become pregnant or suspect she is pregnant while she or\n             her partner is participating in this study, she should inform her treating physician\n             immediately\n\n        Exclusion Criteria:\n\n        -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "4 Months"
        }, 
        "enrollment": {
            "#text": "42", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02116959", 
            "org_study_id": "13087"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Infants", 
                    "Babies"
                ], 
                "intervention_name": "Melphalan", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Infants", 
                    "Babies"
                ], 
                "intervention_name": "Carboplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Infants", 
                    "Babies"
                ], 
                "intervention_name": "Etoposide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Infants", 
                    "Babies"
                ], 
                "intervention_name": "Vincristine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Etoposide", 
                "Vincristine", 
                "Melphalan", 
                "Carboplatin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Systemic", 
            "Chemotherapy", 
            "Melphalan"
        ], 
        "lastchanged_date": "April 24, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "San Francisco", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94143"
                }, 
                "name": "University of California, San Francisco"
            }, 
            "investigator": [
                {
                    "last_name": "Steven Dubois, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Sheila Thampi, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Steven Hetts, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Van Halbach, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Bertil Damato, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Alejandra de Alba Campomanes, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Elizabeth Robbins, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Anuradha Banerjee, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Janel Long-Boyle, PhD, PharmD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Ilana Withop, RN, PNP", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Pilot Study Evaluating the Safety of Alternating Systemic Chemotherapy and Intra-Arterial Melphalan Chemotherapy in Children With Newly Diagnosed Advanced Intra-Ocular Retinoblastoma", 
        "other_outcome": {
            "measure": "Collection of melphalan pharmacokinetics after intra-arterial administration to the retina", 
            "safety_issue": "No", 
            "time_frame": "Up to 2 years"
        }, 
        "overall_contact": {
            "email": "matthayk@peds.ucsf.edu", 
            "last_name": "Katherine Matthay, MD", 
            "phone": "415-476-3831"
        }, 
        "overall_contact_backup": {
            "email": "alcantaro@cc.ucsf.edu", 
            "last_name": "Oscar Alcantar", 
            "phone": "415-476-2218"
        }, 
        "overall_official": {
            "affiliation": "University of California, San Francisco", 
            "last_name": "Katherine Matthay, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Adverse Event evaluation for newly diagnosed advanced retinoblastoma treated with melphalan therapy and systemic chemotherapy", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "measure": "Evaluation of patients' commitment to taking the study medication", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "measure": "Dose-Limiting Toxicity (DLT) and minimum tolerated dosing interval for combination IAM and CEV.", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 2 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02116959"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Response rates after IAM combined with systemic CEV in patients with newly diagnosed advanced intraocular retinoblastoma", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "measure": "Ocular event free survival with the use of combination IAM therapy and systemic CEV in this patient population.", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "measure": "Visual outcomes using a standardized age based assessment", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 2 years"
            }
        ], 
        "source": "University of California, San Francisco", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of California, San Francisco", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}